Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.77 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.70 |
| ▸ | USP2 | O75604 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.66 |
| ▸ | OSBP | P22059 | 1/20 | 0.66 |
| ▸ | RORC | P51449 | 1/20 | 0.66 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.66 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.64 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3953202 | 1.00 | POLA1 (0.77) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL27319672 | 1.00 | POLA1 (0.77) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL25353099 | 1.00 | POLA1 (0.77) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL5386706 | 1.00 | POLA1 (0.77) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL3954234 | 0.98 | POLA1 (0.77) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL3954232 | 0.98 | POLA1 (0.77) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL25351944 | 0.98 | POLA1 (0.77) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL2134010 | 0.98 | POLA1 (0.77) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL27319635 | 0.98 | POLA1 (0.77) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL11426770 | 0.98 | POLA1 (0.75) | POLA1CYP46A1USP2LMNAABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110577557-B | Sialic acid lipid derivative and preparation method and application thereof | 沈阳药科大学 | 2022-03-11 | — | — | CN | disclosed |
| CN-110577557-A | sialic acid lipid derivative and preparation method and application thereof | 沈阳药科大学 | 2019-12-17 | — | — | CN | disclosed |
| EP-1670838-B1 | AMPHIPHILIC BLOCK COPOLYMER AND POLYMERIC COMPOSITION COMPRISING THE SAME FOR DRUG DELIVERY | SAMYANG BIOPHARMACEUTICALS (KR) | 2015-12-09 | — | — | EP | disclosed |
| US-8349306-B2 | Hydrophilic comonomers of alkylene glycol, vinyl alcohols, vinylpyrrolidone, and/or acrylamide; hydrophobic comonoomer of lactic acid, glycolic acid, 6-hydroxycaproic acid, and/or dioxan-2-one substituted with tocopherol or cholesterol; stable micelles for delivery of anticarcinogenic agents | SAMYANG BIOPHARMACEUTICALS CORPORATION (KR) | 2013-01-08 | — | — | US | disclosed |
| EP-1670838-A4 | AMPHIPHILIC BLOCK COPOLYMER AND POLYMERIC COMPOSITION COMPRISING THE SAME FOR DRUG DELIVERY | SAMYANG CORP (KR) | 2009-07-08 | — | — | EP | disclosed |
| CN-100471886-C | Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery | SAMYANG CORP (KR) | 2009-03-25 | — | — | CN | disclosed |
| US-20080152616-A1 | Amphiphilic block copolymer and polymeric compostition comprising the same for drug delivery | SAMYANG HOLDINGS CORPORATION (KR) | 2008-06-26 | — | — | US | disclosed |
| US-7311901-B2 | Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery | SAMYANG CORPORATION (KR) | 2007-12-25 | — | — | US | disclosed |
| EP-1670838-A1 | AMPHIPHILIC BLOCK COPOLYMER AND POLYMERIC COMPOSITION COMPRISING THE SAME FOR DRUG DELIVERY | Samyang Corporation (KR) | 2006-06-21 | — | — | EP | disclosed |
| CN-1780865-A | Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery | SAMYANG CORP (KR) | 2006-05-31 | — | — | CN | disclosed |
| US-20050201972-A1 | Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery | SAMYANG CORPORATION | 2005-09-15 | — | — | US | disclosed |
| WO-2005035606-A1 | AMPHIPHILIC BLOCK COPOLYMER AND POLYMERIC COMPOSITION COMPRISING THE SAME FOR DRUG DELIVERY | SAMYANG CORPORATION (KR) | 2005-04-21 | — | — | WO | disclosed |
| US-20030064948-A1 | Invasomes for therapy of disorders, their preparation and use | VECTRON THERAPEUTICS AG (DE) | 2003-04-03 | — | — | US | disclosed |
| WO-1997004748-A9 | ENHANCED ARTIFICIAL VIRAL ENVELOPES FOR CELLULAR DELIVERY OF THERAPEUTIC SUBSTANCES | — | 1997-10-09 | — | — | WO | disclosed |
| WO-1997004748-A2 | ENHANCED ARTIFICIAL VIRAL ENVELOPES FOR CELLULAR DELIVERY OF THERAPEUTIC SUBSTANCES | ADVANCED THERAPIES, INC. (US) | 1997-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080152616-A1 | Amphiphilic block copolymer and polymeric compostition comprising the same for drug delivery | CETP, ABCB4, TPRKB | POLA1 2142/4885CYP46A1 22/4885USP2 1543/4885 |
| US-20050201972-A1 | Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery | TTPA, CETP, CHKB | POLA1 2927/4885CYP46A1 110/4885USP2 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.